The University of Nevada, Reno School of Medicine

New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma 

MD, MS

Compare programmed cell death protein-1 (PD-1) inhibitors and programmed cell death ligand-1 (PD-L1) inhibitors for cutaneous squamous cell carcinoma (cSCC) based on their mechanism of action  

Review the latest clinical efficacy and safety data for PD-1 and PD-L1 inhibitors in the treatment of advanced cSCC 

small_image (9).png

thumbnail_image (9).png

image (9).png

Skin Cancer

Live Evaluations

FC25: ​​​New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma 

Squamous Cell Carcinoma

FC25: New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures

FC25: ​​​New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma

About

About

Learning Objectives

Learning Objectives

Intended Audience

Intended Audience

Faculty

Faculty

Accreditation Statement

Accreditation Statement

Credit Designation Statement

Credit Designation Statement

Disclosures

Disclosures

FC25: New Checkpoint on the Block: The Latest Evidence for PD-L1 Inhibition in Cutaneous Squamous Cell Carcinoma